Circassia, Ltd.: Series C $25M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Allergy, X - Immunology, X - Vaccines

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Dec

2008

Jado Technologies, GmbH: Series B$4.9M

Posted in I - Series B, Q - 4Q08, R - INTERNATIONAL, X - Allergy, X - Antiinfective

Jado Technologies (Germany) early-stage developer of small molecule allergy and antiinfective therapeutics, closed a $4.9M Series B financing. Participants include Peppermint Financial Partners, NRW Bank, Dresden Fonds, EMBL Ventures, ERP-Startfonds, Max Planck Society and MASA Life Science Ventures.

Dec

2008

ImVision Therapeutics, AG: Series A $4.6M

Posted in I - Series A, Q - 3Q08, R - INTERNATIONAL, X - Allergy, X - Antibody

ImVision Therapeutics (Germany) biopharmaceutical company focused on intralymphatic immunotherapy for allergies, closed a $4.6M Series A financing. Participants include Aravis Venture Associates AG and Nextech Venture.

Nov

2008

RegImmune, Inc.: Series B $8M

Posted in I - Series B, Q - 2Q08, R - WEST, X - Allergy, X - Autoimmune, X - Inflammation

RegImmune (Mountain View, CA) early-stage biopharmaceutical company focused on the treatment of graft versus host disease, allergies, autoimmune diseases and other inflammatory diseases, closed a $8M Series B financing. Participants include NIF SMBC Ventures, CSK Venture Capital, Japan Asia Investment Co, and Yasuda Enterprise Development Co.

to top of page...